Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) had its price target increased by BMO Capital Markets from $16.00 to $17.00 in a research note published on Monday. The brokerage currently has a market perform rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also recently issued reports on the stock. Piper Jaffray Companies reaffirmed a sell rating and issued a $12.00 price objective on shares of Valeant Pharmaceuticals Intl in a research note on Friday. HC Wainwright reaffirmed a hold rating and issued a $17.00 price objective on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, November 9th. TheStreet raised shares of Valeant Pharmaceuticals Intl from a d rating to a c- rating in a research note on Tuesday, November 7th. Royal Bank Of Canada set a $18.00 price objective on shares of Valeant Pharmaceuticals Intl and gave the company a sector perform rating in a research note on Wednesday, November 8th. Finally, Deutsche Bank AG reaffirmed a hold rating and issued a $19.00 price objective on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, November 8th. Five equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $17.22.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded down $0.78 during trading on Monday, hitting $14.60. 19,821,000 shares of the stock were exchanged, compared to its average volume of 18,006,918. Valeant Pharmaceuticals Intl has a 12 month low of $8.31 and a 12 month high of $18.71. The stock has a market cap of $4,960.00, a PE ratio of 2.50, a price-to-earnings-growth ratio of 0.43 and a beta of -0.40. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/valeant-pharmaceuticals-intl-inc-vrx-price-target-raised-to-17-00-at-bmo-capital-markets/1703277.html.

In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was bought at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the purchase, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.87% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. Paulson & CO. Inc. increased its stake in Valeant Pharmaceuticals Intl by 12.5% during the 2nd quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after purchasing an additional 2,428,900 shares in the last quarter. Vanguard Group Inc. increased its stake in Valeant Pharmaceuticals Intl by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock valued at $125,853,000 after purchasing an additional 294,643 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Valeant Pharmaceuticals Intl by 327.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock valued at $64,086,000 after purchasing an additional 3,426,410 shares in the last quarter. CIBC World Markets Inc. increased its stake in Valeant Pharmaceuticals Intl by 2.3% during the 2nd quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock valued at $64,726,000 after purchasing an additional 83,592 shares in the last quarter. Finally, Chou Associates Management Inc. increased its stake in Valeant Pharmaceuticals Intl by 29.7% during the 2nd quarter. Chou Associates Management Inc. now owns 3,053,843 shares of the specialty pharmaceutical company’s stock valued at $53,030,000 after purchasing an additional 700,000 shares in the last quarter. Institutional investors and hedge funds own 46.61% of the company’s stock.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.